$CADL SEC Filings

Filed On	Filing
02 Oct 2026	Form 4: Loggia Nicoletta, Director Granted 380 Stock Option (Right to Buy) ($3.3K)
02 Oct 2026	Form 4: Papa Joseph C, Director Granted 1,325 Stock Option (Right to Buy) ($11.5K)
02 Oct 2026	Form 4: Manning Paul B, Director Granted 2,189 Stock Option (Right to Buy) ($19K)
11 Sep 2026	Form 4: Tak Paul Peter, Director Received 125,000 shares by exercise or conversion ($194K) · Sold 220,866 shares ($2.54M) · Sold 59,379 shares ($621K)
10 Sep 2026	144
10 Sep 2026	Form 4: Zimmermann Martine, Director Granted 64,000 Stock Option (Right to Buy)
10 Sep 2026	Form 3: Zimmermann Martine, Director No securities owned
10 Sep 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness
09 Sep 2026	8-K: Regulation FD Disclosure Exhibit 99.1 Tipping the balance in favor of the immune system to fight cancer NASDAQ: CADL Corporate Presentation \| September 2026 © © 2026 2026 by by C Ca an ndel del T Ther hera ap peu eut ti ic cs s
19 Aug 2026	Form 4: Tyagarajan Seshu, Chief Technology Officer Sold 7,000 shares ($84K)
17 Aug 2026	144
13 Aug 2026	10-Q
13 Aug 2026	8-K: Results of Operations and Financial Condition
27 Jul 2026	SCHEDULE 13G
08 Jul 2026	Form 4: Sims Mark E., Chief Commercial Officer Granted 285,000 Stock Option (Right to Buy)
08 Jul 2026	Form 3: Sims Mark E., Chief Commercial Officer No securities owned
01 Jul 2026	Form 4: Barone Francesca, Chief Scientific Officer Sold 23,447 shares ($236K)
01 Jul 2026	Form 4: Tyagarajan Seshu, Chief Technology Officer Sold 7,000 shares ($70.2K)
01 Jul 2026	Form 4: Manning Paul B, Director Granted 2,199 Stock Option (Right to Buy) ($19K)
01 Jul 2026	Form 4: Papa Joseph C, Director Granted 1,331 Stock Option (Right to Buy) ($11.5K)

Comments